Results 151 to 160 of about 99,677 (264)

Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
This review synthesizes current mechanistic and clinical evidence on IL‐6 inhibitors, particularly sarilumab and tocilizumab, concerning their effect on pain in RA. ABSTRACT Rheumatoid arthritis (RA) is an autoimmune systemic disease in which pain remains a major and often refractory symptom even after clinical remission of the disease.
Andrej Belančić, Seher Sener, Almir Fajkić, Ines Potočnjak, Mirjana Stanić Benić, Marijana Vučković, Yusuf Ziya Sener, Marija Rogoznica Pavlović, Antonio Markotić, Josipa Radić, Mislav Radić   +10 more
wiley   +1 more source

Spontaneous Regression of Metastatic Colorectal Cancer Following Discontinuation of an Interleukin-6 Receptor Inhibitor: A Case Report. [PDF]

Surg Case Rep
Miyake E, Taniguchi F, Nosaka M, Mouri K, Sato M, Kajioka H, Ogawa T, Watanabe M, Katsuda K, Iseki A, Sato Y, Tanakaya K, Aoki H.   +12 more
europepmc   +1 more source

A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma. [PDF]

IJU Case Rep
ABSTRACT Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported. Differentiating early CRS from an infusion‐related reaction (IRR) is clinically challenging, particularly ...
Shibata R, Mochizuki T, Kawahara T, Morikawa T, Kiuchi H, Hanai T, Teranishi JI, Chiba K.   +7 more
europepmc   +2 more sources

Consortium‐Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit‐Focused Impact Evaluation of the PHOSP‐COVID Study

Health Expectations, Volume 29, Issue 2, April 2026.
ABSTRACT Background At the start of the coronavirus disease‐2019 (COVID‐19) pandemic in early 2020, the long‐term outcomes for survivors of COVID‐19 were unknown. The PHOSP‐COVID cohort study was set up at scale and pace in Spring 2020 to determine the short‐ to long‐term health consequences of COVID‐19 in post‐hospitalisation survivors; to understand ...
Linzy Houchen‐Wolloff, Joanna Bell, Rebecca Pritchard, Krisnah Poinasamy, Kate Holmes, Samantha Walker, Nikki Smith, Claire Hastie, Natalie Rogers, Dawn Adams, Rashmita Nathu, Rhyan Gill, Jenny Bunker, Lily Staunton, James Chalmers, Ling‐Pei Ho, Victoria Harris, Alexander Horsley, Michael Marks, Betty Raman, Louise V. Wain, Christopher Brightling, Rachael Evans   +22 more
wiley   +1 more source

Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection – Case Series Report

Infection and Drug Resistance
Chunlan Fu,1 Yuanyuan Zhu,2 Weijia Huang,2 Yi Luo,2 Yongxian Hu,2 He Huang,2 Jie Sun2 1Department of Hematology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, Zhejiang, 311800, People’s Republic of China; 2Transplantation Center, The ...
Fu C, Zhu Y, Huang W, Luo Y, Hu Y, Huang H, Sun J   +6 more
doaj  

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome. [PDF]

Crit Care Explor
Filippini DFL, Khyali J, Janssen M, Rademaker E, Cremer OL, van der Poll T, van Amstel RBE, Endeman H, Bos LDJ, Amsterdam UMC COVID-19 Biobank Study Group.   +9 more
europepmc   +1 more source

NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment [PDF]

, 2011
Ades, A E, Dias, Sofia, Sutton, Alex J, Welton, Nicky J   +3 more
core   +2 more sources

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vasculitis flares and irAEs in this population.
Juan Sevillano, Noha Abdel‐Wahab, Yixuan Zhou, Juan I. Ruiz, Maria E. Suarez‐Almazor   +4 more
wiley   +1 more source

Fulminant Amyloid β-Related Angiitis With Herniation and Rapid Response to Tocilizumab: A Case Report. [PDF]

Neurol Neuroimmunol Neuroinflamm
Nguyen JV, Byrne EM, Yuan S, Bhattacharyya S, Kozberg MG, Lukacs M, Bilodeau PA.   +6 more
europepmc   +1 more source

Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective To characterize clinical and transcriptomic differences in juvenile scleromyositis overlap (jOverlap) compared to juvenile systemic sclerosis (jSSc) and juvenile dermatomyositis (JDM), focusing on autoantibody profiles, organ involvement, treatment, and peripheral blood gene expression.
Amanda D. Robinson, Clare E. Pain, Gabrielle A. Morgan, Anwesha Sanyal, Srilakshmi Chaparala, Lauren M. Pachman, Kathryn S. Torok   +6 more
wiley   +1 more source